Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Monday, September 30, 2019
Horizon Discovery Group announced the full commercial licensing to Glenmark of its gene-edited Glutamine Synthetase knockout Chinese Hamster Ovary K1 cell line.
read more
Horizon Discovery has signed a collaboration and license agreement with Mammoth Biosciences to access Mammoth’s novel CRISPR platform.
read more
Wednesday, April 15, 2020
Horizon Discovery announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE™ platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-...
read more
Monday, December 14, 2020
Horizon Discovery Group has granted two commercial licenses for its cGMP-compliant CHOSOURCE platform to Sanyou Biopharmaceuticals.
read more
Wednesday, August 05, 2020
Horizon Discovery announced TrueBinding has signed a set of commercial licenses for Horizon’s cGMP-compliant CHOSOURCE platform.
read more
Horizon Discovery Group has announced the addition of single cell RNAseq-linked pooled CRISPR screening to its CRISPR screening services portfolio.
read more
Monday, November 17, 2014
Horizon Discovery Group plc (LSE: HZD) (Horizon), a leading provider of research tools to support translational genomics, , has today announced the formation of a new Scientific Advisory Board (SAB) for its Diagnostics Business Unit (Horizon ...
read more
Tuesday, January 21, 2020
Horizon Discovery Group will license its gene-edited Glutamine Synthetase knockout CHO K1 cell line to NGM Biopharmaceuticals.
read more
Horizon Discovery Group announced the addition of an arrayed CRISPR knockout screening service for primary human B cells to its cell-based screening services.
read more
Monday, February 12, 2018
Horizon Discovery Group announces that it has entered into a non-exclusive out-licensing agreement with a US-based immuno-oncology therapeutics developer.
read more
Horizon Discovery Group announced its cGMP-compliant CHOSOURCE™ platform has played a key role in generating a stable cell line for the development of an immunotherapy for autoimmune diseases.
read more
Horizon Discovery Group announced the introduction of its stably expressing Cas9 and dCas9-VPR cell lines.
read more
Wednesday, January 02, 2019
HOOKIPA Pharma announced that it has achieved its first research milestone in its collaboration and license agreement with Gilead Sciences.
read more
Hongene Biotech Corporation entered a non-exclusive licensing agreement with the UMass Chan Medical School to produce and supply extended nucleic acid (exNA) monomers and exNA-modified oligonucleotides for research use.
read more
Hongene has appointed Dr. Pieter Cullis, a renowned innovator in lipid nanoparticle (LNP) drug delivery, to its scientific advisory board. This strategic addition reinforces Hongene’s commitment to advancing RNA therapeutics.
read more